During the last session, Mineralys Therapeutics Inc (NASDAQ:MLYS)’s traded shares were 0.61 million, with the beta value of the company hitting 1.08. At the end of the trading day, the stock’s price was $10.52, reflecting an intraday loss of -0.19% or -$0.02. The 52-week high for the MLYS share is $15.25, that puts it down -44.96 from that peak though still a striking 21.67% gain since the share price plummeted to a 52-week low of $8.24. The company’s market capitalization is $524.27M, and the average trade volume was 273.80K shares over the past three months.
Mineralys Therapeutics Inc (MLYS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. MLYS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.08.
Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information
Mineralys Therapeutics Inc (MLYS) registered a -0.19% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.19% in intraday trading to $10.52, hitting a weekly high. The stock’s 5-day price performance is 15.10%, and it has moved by 2.53% in 30 days. Based on these gigs, the overall price performance for the year is -27.95%.
The consensus price target of analysts on Wall Street is $30, which implies an increase of 64.93% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $30 and $30 respectively. As a result, MLYS is trading at a discount of -185.17% off the target high and -185.17% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -170.42%. While earnings are projected to return -7.43% in 2025, the next five years will return -2.73% per annum.
MLYS Dividends
Mineralys Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 5.07 million shares, is of SAMSARA BIOCAPITAL, LLC’s that is approximately 10.2822% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $59.38 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mineralys Therapeutics Inc (MLYS) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 784.65 shares. This amounts to just over 1.57 percent of the company’s overall shares, with a $8.25 million market value. The same data shows that the other fund manager holds slightly less at 781.46, or about 1.57% of the stock, which is worth about $8.22 million.
